血液透析并发心力衰竭的防治新进展  

New progress in the prevention and treatment of heart failure in hemodialysis patients

作　　者：刘卫华[1] 林紫宁 洪富源[1] LIU Wei-hua;LIN Zi-ning;HONG Fu-yuan(Provincial Clinical Medical College of Fujian Medical University,Department of Nephrology,Fujian Provinical Hospital,Fuzhou 350001,China)

机构地区：[1]福建医科大学省立临床医学院福建省立医院肾内科,福建福州350001

出　　处：《中国实用内科杂志》2021年第11期917-921,共5页Chinese Journal of Practical Internal Medicine

基　　金：福建省自然科学基金(2019J01185)。

摘　　要：心血管疾病(CVD)是终末期肾脏病(ESRD)血液透析患者的主要并发症。血液透析患者的心血管并发症可以分为两类:一类是心脏血管病变,常见如动脉粥样硬化;二是心肌病变,导致心脏本身结构和功能的改变,如心室肥厚和心脏扩张,而心力衰竭是这些过程的共同结果。由此可见,控制心力衰竭是提高血液透析质量和延长血液透析患者生存率的重中之重,文章从血液透析患者心力衰竭的危险因素、症状及防治方面的新进展做一简述。Cardiovascular complication(CVD)is a major complication in hemodialysis patients with end-stage renal disease(ESRD). Vascular complications in hemodialysis patients can be divided into two categories: cardiac vascular disease,such as atherosclerosis and cardiomyopathy,which results in changes in the structure and function of the heart itself,such as ventricular hypertrophy,and cardiac dilatation,and heart failure is a common result of these processes. It can be concluded that the control of heart failure is the top priority to improve the quality of hemodialysis and prolong the life of hemodialysis patients. In this paper,the risk factors,symptoms and new progress in prevention and treatment of heart failure in hemodialysis patients are summarized.

关 键 词：血液透析 心力衰竭 终末期肾脏病 

分 类 号：R459.5[医药卫生—治疗学]